Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combinations of Pharmacologic Smoking Cessation Treatments

This study has been completed.
Sponsor:
Information provided by:
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00018187
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: May 2007
  Purpose

The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.


Condition Intervention Phase
Smoking
Drug: Bupropion
Drug: Mecamylamine
Drug: Nicotine Patch
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Combinations of Pharmacologic Smoking Cessation Treatments

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Study Start Date: November 1998
Estimated Study Completion Date: June 2001
  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Subjects must be a smoker between 20 and 40 years old, have smoked at least 20 cigarettes per day for at least 2 years, wish to stop smoking and be in good general health

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018187

Locations
United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073
Sponsors and Collaborators
Investigators
Investigator: Neil Hartman, M.D.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00018187     History of Changes
Other Study ID Numbers: ADRD-011-98S
Study First Received: July 3, 2001
Last Updated: January 20, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Department of Veterans Affairs:
smoking cessation
bupropion
mecamylamine
nicotine

Additional relevant MeSH terms:
Bupropion
Mecamylamine
Nicotine
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Agonists
Cholinergic Antagonists
Dopamine Agents
Dopamine Uptake Inhibitors
Ganglionic Blockers
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Nicotinic Agonists
Nicotinic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014